retatrutide triple agonist weight loss ly3437943 glp-1 gip glucagon mechanism Beyond GLP-1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% loss—surpassing semaglutide & tirzepatide. Evidence-based Retatrutide vs Tirzepatide Compared |
Pay in 4 interest-free payments of $7.13 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11























